Addressing Gender Disparities in Cardiovascular Clinical Trials: A Critical Imperative for Equity and Scientific Rigor

The persistent underrepresentation of women in cardiovascular (CV) clinical trials is a multifactorial issue that continues to compromise scientific validity and equitable health care. Over the past three decades, landmark studies have highlighted the negative implications of this imbalance, from limited applicability of findings to disparate health outcomes. Tackling this disparity requires a systemic, multidimensional strategy – one that spans the spectrum of research infrastructure, clinical practice, and policy reform. Proposed solutions include mandating balanced enrollment targets by funding agencies and regulators to ensure female participation aligns with disease prevalence. Trials should be purposefully designed and sufficiently powered to detect sex-specific differences in efficacy and safety. Removing logistical and societal barriers – such as through decentralized trial designs and flexible scheduling – can improve accessibility for women. Training investigators to recognize and mitigate implicit bias and embedding sex-based education into certification programs are essential for cultural transformation within research teams. Furthermore, robust reporting of sex-disaggregated data must be enforced by journals and regulatory bodies, fostering transparency and accountability in scientific dissemination. Investment in women-centric research – especially in areas such as microvascular disease and heart failure with preserved ejection fraction – is imperative to close long-standing knowledge gaps. Achieving gender equity in clinical trials is not only a moral imperative but also a scientific necessity. A coordinated effort across sectors will strengthen research outcomes, improve clinical practice, and ensure that CV advances benefit all populations equitably.